PharmaCyte Biotech, Inc.
Financial highlights
| Metric | FY 04/30/25 | FY 04/30/24 | FY 04/30/23 | FY 04/30/22 | FY 04/30/21 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $0 | $0 | $0 | $0 | $0 |
| Research and development | $438,416 | $407,431 | $468,536 | $690,937 | $916,249 |
| Operating expenses | $4.4M | $8.5M | $6.5M | $4.4M | $3.6M |
| Operating income | -$4.4M | -$8.5M | -$6.5M | -$4.4M | -$3.6M |
| Interest expense | — | — | $0 | $509 | $3,046 |
| Income tax expense | $0 | $0 | $0 | $0 | $0 |
| Net income | $30.7M | $333,763 | -$4.3M | -$4.2M | -$3.6M |
| Balance Sheet | |||||
| Cash and equivalents | $15.2M | $50.2M | $68.0M | $85.4M | — |
| Current assets | $22.4M | $50.4M | $68.1M | $85.5M | $2.3M |
| Total assets | $55.2M | $59.9M | $73.3M | $90.6M | $7.4M |
| Current liabilities | $2.9M | $7.4M | $586,581 | $704,370 | $724,778 |
| Total liabilities | $3.3M | $20.4M | $586,581 | $704,370 | $724,778 |
| Stockholders' equity | $51.9M | $27.6M | $72.7M | $89.9M | $6.7M |
| Cash Flow Statement | |||||
| Cash from operations | -$3.0M | -$2.2M | -$3.8M | -$4.1M | -$3.3M |
| Stock-based compensation | $478,637 | $674,693 | $7,334 | $33,146 | $194,261 |
| Share repurchases | $2.5M | $28.2M | $13.6M | $0 | — |
Shares outstanding 10.7M · Free float 86.6%
Annual filing data through FY ended April 30, 2025; float as of July 12, 2026.